Pauling Labs

Pauling (also known as Pauling Labs) is a stealth-stage biotechnology company focused on developing a next-generation therapeutics platform that integrates machine learning with high-throughput experimental biology. The company aims to discover and develop novel small molecule drugs for complex biological targets that have historically been considered "undruggable," such as certain transcription factors and protein-protein interactions. Founded by industry veterans and backed by prominent venture capital firms like The Column Group, Pauling leverages its proprietary computational platform to map the relationship between chemical structure and biological function at an unprecedented scale. The company is currently in the pre-clinical stage, building out its initial pipeline of candidates for high-unmet-need indications in oncology and immunology.